Table 1.
Baseline characteristics.
| Variables | Total (n = 70) | No Sarcopenia (n = 23) |
Sarcopenia (n = 47) |
p |
|---|---|---|---|---|
| Age (years) * | 66.5 (60.0, 73.0) | 63.0 (58.0, 70.0) | 68.0 (63.3, 73.0) | 0.070 |
| BMI (km/m2) * | 24.3 (21.7, 25.8) | 25.6 (25.1, 28.6) | 22.4 (21.2, 25.0) | <0.001 |
| Obesity, n † | 29 (41.4%) | 17 (73.9%) | 12 (25.5%) | <0.001 |
| SMI (cm2/m2) * | 49.6 (44.9, 53.1) | 58.1 (53.8, 62.4) | 46.5 (43.7, 48.6) | <0.001 |
| SFI (cm2/m2) * | 38.3 (29.4, 47.9) | 48.1 (38.3, 65.3) | 34.5 (27.8, 45.5) | <0.001 |
| VFI (cm2/m2) * | 47.2 (30.3, 62.8) | 48.5 (37.6, 70.6) | 45.3 (25.0, 62.5) | 0.165 |
| VSR * | 1.09 (0.76, 1.58) | 0.93 (0.82, 1.52) | 1.16 (0.78, 1.59) | 0.516 |
| PSA (ng/mL) * | 299.4 (89.6, 801.3) | 237.3 (94.4, 540.2) | 338.0 (101.7, 1248.7) | 0.241 |
| Treatment agent, n † | 0.353 | |||
| Docetaxel | 42 (60.0%) | 12 (52.2%) | 30 (63.8%) | |
| Abiraterone acetate | 28 (40.0%) | 11 (47.8%) | 17 (36.2%) | |
| ECOG PS > 0, n † | 34 (48.6%) | 10 (43.5%) | 24 (51.1%) | 0.554 |
| Gleason score ≥ 8, n ‡ | 63 (94.0%) | 19 (90.5%) | 44 (95.7%) | 0.584 |
| Stage (cT4), n † | 37 (55.2%) | 16 (69.6%) | 21 (47.7%) | 0.090 |
| Regional LN metastasis, n ‡ | 56 (80.0%) | 22 (95.7%) | 34 (72.3%) | 0.026 |
| Bone metastasis, n ‡ | 58 (82.9%) | 14 (60.9%) | 44 (93.6%) | 0.001 |
| Visceral metastasis, n † | 20 (28.6%) | 7 (30.4%) | 13 (27.7%) | 0.811 |
| High-volume, n † | 56 (80.0%) | 14 (60.9%) | 42 (89.4%) | 0.006 |
| High-risk, n ‡ | 59 (84.3%) | 14 (60.9%) | 45 (95.7%) | <0.001 |
BMI, body mass index; SMI, skeletal muscle index; SFI, subcutaneous fat index; VFI, visceral fat index; VSR, visceral-to-subcutaneous fat ratio; PSA, prostate-specific antigen; ECOG PS, Eastern Cooperative Oncology Group performance status; LN, lymph node. * Mann–Whitney test. Numbers are medians and interquartile ranges in curved brackets. † Chi-squared test. ‡ Fischer’s exact test.